Zobrazeno 1 - 10
of 129
pro vyhledávání: '"59"'
Autor:
E. Mahenthiralingham, G. McElvaney, Jane F. Turton, D. Kenna, M. Ni Chroinin, Audrey Perry, Kirsten Schaffer, Malcolm Brodlie, M.M. Hannan, Barry J. Plant, Jim J. Egan, F.K. Gould, David Mullane, Cedric Gunaratnam, Claire Perry
Publikováno v:
Journal of Cystic Fibrosis. 14:S72
Background Ralstonia mannitolilytica is a rarely reported pathogen in cystic fibrosis. It is frequently resistant to antimicrobials and can be misidentified as Burkholderia cepacia complex using biochemical techniques. Methods We identified 7 CF pati
Publikováno v:
Transplantation Proceedings. 52:1950-1952
Objective Thrombocytopenia is a common condition in patients undergoing liver transplantation (LT). Thrombocytopenia is prevalent in early postoperative phase, and it gradually improves after several weeks. Delayed severe thrombocytopenia occurring a
Autor:
Celina Ledesma, Roy B. Jones, Partow Kebriaei, Chitra Hosing, Issa F. Khouri, Borje S. Andersson, Krina K. Patel, Sairah Ahmed, Stefan O. Ciurea, Qaiser Bashir, Amin M. Alousi, Genevieve Lyons, Betul Oran, Uday R. Popat, Amanda Olson, Elizabeth J. Shpall, Roland L. Bassett, Gabriela Rondon, Nina Shah, David Marin, Muzaffar H. Qazilbash, Richard E. Champlin, Ben C. Valdez, Yago Nieto, Katayoun Rezvani
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:285-292
We investigated the long-term safety and disease control data obtained with i.v. busulfan (Bu) combined with clofarabine (Clo) in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). A
Autor:
Friedrich Kaufmann, Volkmar Falk, Felix Schoenrath, Julia Stein, C. Knosalla, T. Haese, Johanna Mulzer, H. Krastev, Evgenij Potapov, Jan Knierim, Christoph Hoermandinger, M. Müller
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S340
Purpose 6-minute walk distance (6MWD) is a predictor of outcome in patients with left ventricular assist device (LVAD). The aim of this study was to evaluate the exercise capacity and LVAD-flow parameters in relation to right ventricular function. Me
Autor:
Armin Rashidi, Claudio G. Brunstein, Justin A Wasko, Daniel J. Weisdorf, Jeffrey S. Miller, Maryam Ebadi
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S332
HHV-6 reactivation is common after cord blood transplantation (CBT). However, the ability of the new immune system to clear HHV-6 viremias is unknown. A previous study of 23 CBT recipients suggested that ∼50% of patients had detectable HHV-6 by who
Autor:
Mohammad Abu Zaid, Shawn Griffin, Elizabeth A Cox, Caitlin A Schmidt, Kirsten D Ervin, Jennifer E. Schwartz, Bryan J. Brinda, Michael J. Robertson, Rafat Abonour, Vaibhav Agrawal, Lindsey Koch, Sherif S. Farag, Teresa C. Thakrar, Robert P. Nelson
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S249-S250
Corticosteroids are considered the standard first-line treatment for moderate/severe acute graft versus host disease (aGVHD), yet there is no consensus on the optimal management of patients that are steroid-refractory (SR). Infliximab is a chimeric m
Autor:
Reuven Or, Arnon Nagler, Tsila Zuckerman, Avichai Shimoni, Dror Mevorach, Jacob M. Rowe, Inna Reiner, Simcha Samuel
Publikováno v:
Biology of Blood and Marrow Transplantation. 20(1):58-65
Because of its potent immunomodulatory effect, an infusion of donor mononuclear early apoptotic cells (ApoCell) was tested in addition to cyclosporine and methotrexate as prophylaxis for acute graft-versus-host disease (GVHD) after HLA-matched myeloa
Publikováno v:
The Journal of Heart and Lung Transplantation. 23:461-465
Background We compared the use of intravenous ganciclovir and cytomegalovirus hyperimmune globulin (CMVIG) as a pre-emptive treatment for cytomegalovirus (CMV)-positive heart transplant recipients. Methods Of 59 CMV-seropositive adult heart transplan
Autor:
Daobin Zhou, Zhen Cai, D. DeMarco, F. Chen, X. Li, J. Mei, J. Hou, Depei Wu, Jennie Zhang, Xiaoyan Ke, Jie Jin, L. Yu, F. Meng, Xin Du
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:e293-e294
e294 dose adjustments were required prior to rollover, per protocol. Pts were followed for up to 5 years (yrs; including 1 yr spent in MM-021). Baseline ISS stage was calculated for all MM-021 pts with available data (N1⁄4 197). Efficacy and safety
Publikováno v:
Biology of Blood and Marrow Transplantation. 21(2):S355-S356
Background: Reduced-intensity conditioning (RIC) provides graft-versus-disease effect with less treatment related toxicity, making allogeneic hematopoietic stem cell transplantation (HSCT) available to more recipients. The objective was to describe t